Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
Location: United States
Employees: 51-200
Total raised: $321M
Founded date: 2019
Investors 4
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | BioImpact ... | bioimpactc... |
| 04.03.2021 | Taiho Vent... | taihoventu... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.08.2022 | Series B | $221M | - |
| 25.02.2021 | Series A | $100M | - |
Mentions in press and media 25
| Date | Title | Description |
| 31.03.2026 | Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs | Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness. The deal is the latest from Lilly, which is using its GLP-1 windfall to place mo... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 11.02.2026 | Eli Lilly Secures Future with Orna Therapeutics Acquisition | Eli Lilly acquired Orna Therapeutics. The deal totals up to $2.4 billion. This secures groundbreaking circular RNA technology. Orna pioneers *in vivo* cell engineering. Their platform allows the body to generate therapies internally. This b... |
| 09.02.2026 | Фармкомпания Eli Lilly покупает американскую биотех-компанию Orna Therapeutics за $2,4 млрд | Американская фармацевтическая компания Eli Lilly (LLY.N) согласилась купить биотехнологическую компанию Orna Therapeutics за $2,4 млрд наличными, получив доступ к технологии, которая позволяет использовать собственные клетки пациентов для с... |
| 09.02.2026 | Eli Lilly and Company to Acquire Orna Therapeutics, For Up To $2.4 Billion | Eli Lilly and Company (NYSE: LLY) is to acquire Orna Therapeutics, Inc., a Waterotown, Mass.-based biotechnology company dedicated to engineering immune cells in vivo. Under the terms of the agreement, Lilly will acquire Orna, and Orna shar... |
| 09.02.2026 | Haveli Investments Acquires Budge Studios from General Atlantic | Haveli Investments, an Austin-based private equity firm specializing in technology and gaming, acquired Budge Studios, a Montreal, Canada-based developer of digital interactive entertainment for children, from General Atlantic. The amount o... |
| 23.08.2024 | Abogen announced development of Cis-System-based circular RNAs | SUZHOU, China, Aug. 23, 2024 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the "Company") announced a publication titled "Efficient circularization of protein-encoding RNAs via a novel cis-splicing system " i... |
| 30.07.2024 | Orna Therapeutics Appoints Nobel Laureate Carolyn Bertozzi, Ph.D., to Scientific Advisory Board | WATERTOWN, Mass., July 30, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines, including panCAR™ in vivo CAR therapies for oncology and autoimmune dise... |
| 23.05.2024 | Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies | Unifies World-Class Validated Circular RNA and Industry-leading Delivery Technologies to Advance New Category of panCAR™ in vivo CAR RNA Medicines for Oncology and Autoimmune Diseases Amit Munshi to Lead Company as Chief Executive Officer F... |
Show more